Cannabis users who experienced a psychosis are particularly vulnerable to cannabis-related harms, which can include worse psychotic symptoms and more hospitalizations. Unfortunately, few psychosocial interventions exist that aim to decrease these harms. Instead, most focus on ceasing cannabis use which is rarely appealing to cannabis users. Furthermore, face-to-face psychotherapy often remains inaccessible to people with psychosis mostly due to lack of trained clinicians. Alternatives such as e-interventions have the potential to increase access to treatment and decrease clinicians' workload. Among cannabis harm reduction approaches are the protective behavioural strategies. These strategies do not encourage nor discourage cannabis use. Instead, they recommend behaviours for safer cannabis use. For example, these strategies include: 1) avoid driving a car under the influence of cannabis, 2) avoid mixing cannabis with other drugs and 3) purchase cannabis only from a trusted source. In the present pan-Canadian study, we will test the first e-intervention called CHAMPS (Cannabis Harm-reducing App for Managing Practices Safely) for cannabis harm reduction adapted for young adult cannabis users who experienced a psychosis. CHAMPS is a smartphone application that includes 17 strategies for safer cannabis use, a personalized consumption goal and a consumption journal. The goals of this study are 1) to confirm whether CHAMPS is acceptable to participants and 2) to test whether it works, notably by positively impacting participants' health and cannabis consumption habits.
This multicentric, two-arm, open-labelled, pilot randomized controlled trial involves 100 young cannabis users who experienced a psychosis and are followed in an early intervention service (EIS) in Canada. Participants will be randomized in a 1:1 ratio to one of two interventions: * CHAMPS and EIS * EIS alone The smartphone application CHAMPS contains six modules (each lasting 15-20 min, weeks 1 to 6) and a booster session (20 min, week 10) based on motivational interviewing and harm reduction approaches. EIS consists of standard of care and psychoeducation material on cannabis use offered in first episode psychosis clinics and administered through in-person visits and/or phone or video calls. All participants will be assessed for a follow-up at weeks 6, 12 and 18. Data on mental health, substance use, cannabis dependence severity, cannabis-related problems, quality of life and health care service utilization will be obtained through questionnaires and medical charts.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
101
CHAMPS provides personalized feedback on participants' cannabis use behaviors and supports strategies to change such behaviors. It comprises six modules measuring the use of cannabis protective behavioural strategies, exploring the possible benefits of changing cannabis practices and setting and monitoring the reach of a SMART cannabis use goal.
Foothills Medical Centre Early Psychosis Intervention Program, Unit 24, 1403-29 Street NW
Calgary, Alberta, Canada
Nova Scotia Early Psychosis Program, 3rd Floor, Abbie Lane Bldg 5909 Veterans' Memorial Lane
Halifax, Nova Scotia, Canada
Clinic Connec-T - Institut universitaire en santé mentale de Montréal, 7401 rue Hochelaga
Montreal, Quebec, Canada
Clinique JAP, Centre hospitalier de l'Université de Montréal, 1051, rue Sanguinet
Montreal, Quebec, Canada
Clinic Notre-Dame des Victoires - Centre de Recherche CERVO, 2601 chemin de la Canardière
Québec, Quebec, Canada
Completion rates
Proportions of participants completing at least the first four CHAMPS modules or with ongoing participation in EIS.
Time frame: Week 12
Retention rates
Proportions of participants retained in the trial (completing all endpoint assessments)
Time frame: Week 6
Acceptability (CHAMPS usage data)
Number of CHAMPS modules completed, time spent on each module, time elapsed between module initiation and completion, total time spent on CHAMPS
Time frame: Weeks -2-0 (baseline) to 10
Participant satisfaction
Score on the Client Satisfaction Questionnaire-I
Time frame: Weeks 6 and 12
Numbers of participants who are referred, screened, eligible, consenting, randomized, initiating and completing the study
Trial parameters
Time frame: Weeks -4 to 18
Efficacy (use of cannabis protective behavioral strategies)
Change between endpoint and baseline scores on the Short Form Protective Behavioral Strategies-Marijuana questionnaire.
Time frame: Weeks -2-0 (baseline), 6, 12 and 18
Efficacy (motivation to change cannabis protective behavioral strategies)
Change between endpoint and baseline scores on the Readiness-to-Change Questionnaire modified for cannabis use
Time frame: Weeks -2-0 (baseline), 6, 12 and 18
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.